The dual, allosteric activator of EP300 and CREBBP I-CBP112 increases histone acetylation, mainly at H3K18, and impairs prostate cancer cell proliferation when applied at a low micromolar concentration [55]. This evidence concerns the gene EP300 and prostate cancer.